Literature DB >> 35022210

Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management.

Andreas B Gevaert1,2,3, Rachna Kataria4, Faiez Zannad5,6, Andrew J Sauer7, Kevin Damman2, Kavita Sharma8, Sanjiv J Shah9, Harriette G C Van Spall10,11,12.   

Abstract

It is estimated that half of all patients with heart failure (HF) have HF with preserved ejection fraction (HFpEF). Yet this form of HF remains a diagnostic and therapeutic challenge. Differentiating HFpEF from other causes of dyspnoea may require advanced diagnostic methods, such as exercise echocardiography, invasive haemodynamics and investigations for 'HFpEF mimickers'. While the classification of HF has relied heavily on cut-points in left ventricular ejection fraction (LVEF), recent evidence points towards a gradual shift in underlying mechanisms, phenotypes and response to therapies as LVEF increases. For example, among patients with HF, the proportion of hospitalisations and deaths due to cardiac causes decreases as LVEF increases. Medication classes that are efficacious in HF with reduced ejection fraction (HFrEF) have been less so at higher LVEF ranges, decreasing the risk of HF hospitalisation but not cardiovascular or all-cause death in HFpEF. These observations reflect the burden of non-cardiac comorbidities as LVEF increases and highlight the complex pathophysiological mechanisms, both cardiac and non-cardiac, underpinning HFpEF. Treatment with sodium-glucose cotransporter 2 inhibitors reduces the risk of composite cardiovascular events, driven by a reduction in HF hospitalisations; renin-angiotensin-aldosterone blockers and angiotensin-neprilysin inhibitors result in smaller reductions in HF hospitalisations among patients with HFpEF. Comprehensive management of HFpEF includes exercise as well as treatment of risk factors and comorbidities. Classification based on phenotypes may facilitate a more targeted approach to treatment than LVEF categorisation, which sets arbitrary cut-points when LVEF is a continuum. This narrative review summarises the pathophysiology, diagnosis, classification and management of patients with HFpEF. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  clinical; diagnostic imaging; diastolic; health care; heart failure; outcome assessment; pharmacology

Mesh:

Substances:

Year:  2022        PMID: 35022210     DOI: 10.1136/heartjnl-2021-319605

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   7.365


  7 in total

Review 1.  Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?

Authors:  Christian A Schneider; Roman Pfister
Journal:  Herz       Date:  2022-08-26       Impact factor: 1.740

Review 2.  Fibrotic Signaling in Cardiac Fibroblasts and Vascular Smooth Muscle Cells: The Dual Roles of Fibrosis in HFpEF and CAD.

Authors:  Julian C Bachmann; Simon J Baumgart; Anna K Uryga; Markus H Bosteen; Giulia Borghetti; Michael Nyberg; Kate M Herum
Journal:  Cells       Date:  2022-05-17       Impact factor: 7.666

Review 3.  The Canadian Women's Heart Health Alliance Atlas on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women - Chapter 6: Sex- and Gender-Specific Diagnosis and Treatment.

Authors:  Monica Parry; Harriette G C Van Spall; Kerri-Anne Mullen; Sharon L Mulvagh; Christine Pacheco; Tracey J F Colella; Marie-Annick Clavel; Shahin Jaffer; Heather J A Foulds; Jasmine Grewal; Marsha Hardy; Jennifer A D Price; Anna L E Levinsson; Christine A Gonsalves; Colleen M Norris
Journal:  CJC Open       Date:  2022-04-19

4.  Redefining Heart Failure in Breast Cancer.

Authors:  Annabelle Santos Volgman; Christine Brezden-Masley; Tochi Okwuosa
Journal:  JACC CardioOncol       Date:  2022-03-15

5.  Iron Deficiency Impacts Diastolic Function, Aerobic Exercise Capacity, and Patient Phenotyping in Heart Failure With Preserved Ejection Fraction: A Subanalysis of the OptimEx-Clin Study.

Authors:  Andreas B Gevaert; Stephan Mueller; Ephraim B Winzer; André Duvinage; Caroline M Van de Heyning; Elisabeth Pieske-Kraigher; Paul J Beckers; Frank Edelmann; Ulrik Wisløff; Burkert Pieske; Volker Adams; Martin Halle; Emeline M Van Craenenbroeck
Journal:  Front Physiol       Date:  2022-02-10       Impact factor: 4.566

6.  Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain.

Authors:  Carlos Escobar; Beatriz Palacios; Luis Varela; Martín Gutiérrez; Mai Duong; Hungta Chen; Nahila Justo; Javier Cid-Ruzafa; Ignacio Hernández; Phillip R Hunt; Juan F Delgado
Journal:  J Clin Med       Date:  2022-09-02       Impact factor: 4.964

7.  Independent and joint association of N-terminal pro-B-type natriuretic peptide and left ventricular mass index with heart failure risk in elderly diabetic patients with right ventricular pacing.

Authors:  Yu Yu; Hao Huang; Sijing Cheng; Yu Deng; Xi Liu; Min Gu; Xuhua Chen; Hongxia Niu; Chi Cai; Wei Hua
Journal:  Front Cardiovasc Med       Date:  2022-07-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.